MASTERCARD
Bringing together the journeys of some of the world’s most inspiring female leaders in arts, sports, politics, hospitality, financial services and beyond, Mastercard has unveiled a coffee-table book, ‘Lasting Legacy - Honoring 25 Visionaries to Celebrate 25 Years of Priceless’. Launched during Women’s Month 2023, the book marks the 25th anniversary of Mastercard’s renowned Priceless platform, which has been connecting people to their passions for a quarter of a century.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005890/en/
Mastercard Lasting Legacy Book (Photo: AETOSWire)
Mastercard is committed to creating a more equitable world for all and this project marks the company’s latest milestone in unlocking opportunities and celebrating the role of women in society. By exploring the role of these trailblazers, the book aims to inspire readers to take action in their own lives and communities to close the gender gap and create a more inclusive future.
The legacy piece highlights the journeys and impact of women including Her Excellency Dr. Aisha Bint Butti Bin Bishr, Global Digital Magnate, Vice Chairwoman of Emaar Development Board & Former Founding Director General of Smart Dubai; Nona Gaprindashvili, Chess Legend; Dr. Maya Morsy, President, Egypt's National Council for Women; Raha Moharrak, Adventurer; Sarah Baydoun, Founder and Creative Director of Sarah’s Bag; Jessica Kahawaty, Philanthropist, Entrepreneur and Model; Laila Mostafa Abdullatif, Director General of Emirates Nature-WWF; Valeriya Ionan, Deputy Minister for Eurointegration at the Ministry of Digital Transformation of Ukraine, and Naoko Yamazaki, Astronaut & Engineer, among others.
“This book has been a true labor of love for us, and a testament to the women who are driving progress and uplifting communities around the world. It is our hope that the stories in ‘Lasting Legacy’ will encourage readers, regardless of their gender, to pursue their passions and make a positive impact on society, to inspire generations to come,” said Beatrice Cornacchia, Senior Vice President, Marketing and Communications, Eastern Europe, Middle East and Africa, Mastercard.
‘Lasting Legacy - Honoring 25 Visionaries to Celebrate 25 Years of Priceless’ represents the evolution of Mastercard's Priceless platform, which has progressed to reflect the company’s ongoing transformation and the changing world of consumers.
For more information on the book’s availability and to read the full interviews, visit here.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005890/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation21.10.2025 12:00:00 CEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and leader in sustainable product innovation, to accelerate the development of IFF’s Designed Enzymatic Biomaterials™ technology platform and create next-generation enzyme technologies for fabric, dish and personal care as well as industrial cleaning applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021911702/en/ Photo credit: IFF This collaboration brings together two industry leaders with a shared vision: to develop high-performance, sustainable solutions that meet evolving consumer and market demands. By combining advanced chemical capabilities and expertise in biotechnology and protein engineering from IFF and BASF, the partnership aims to deliver breakthrough solutions at scale that enhance cleaning performance, imp
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 11:12:00 CEST | Press release
This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression of progressive supranuclear palsy (PSP)The study is being conducted across 44 centers in the European Union, the United Kingdom, and the United StatesThe study reinforces Ferrer’s commitment to researching and developing transformative therapeutic solutions for people with rare neurological diseases Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 10:51:00 CEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 10:00:00 CEST | Press release
Investment in European infrastructure strengthens Impartner’s EMEA operations and commitment to data security and regional growth Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azu
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 10:00:00 CEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom